FPT Software and Vilja Join Forces to Advance Digital Banking
10.9.2024 08:21:00 CEST | Business Wire | Press release
Global IT company FPT Software recently announced a strategic partnership with Nordic-leading core banking service provider, Vilja. As a global technology partner to Vilja, FPT Software aims to fortify its financial services portfolio to deliver more innovative digital banking solutions to customers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909234829/en/
The signing ceremony took place at the Vietnam-Sweden Economic Forum in Stockholm, Sweden. (Photo: Business Wire)
Leveraging FPT Software's extensive technical expertise and global reach, this partnership will introduce Vilja’s cloud-native, application programming interface (API)-first banking platform to global enterprises, with an initial focus on Asia's rapidly growing digital economy. This collaboration also includes the establishment of an R&D center in Asia, dedicated to pioneering diverse innovations that cater to the evolving demands of digital banking, particularly in areas like deposits and loans.
“With over two decades of experience in delivering digital solutions to global leaders in BFSI, FPT Software is confident that our partnership with Vilja will further empower financial institutions with enhanced security, scalability, and user experience. By combining our industry expertise and global presence with Vilja's innovative solutions, we aim to set new standards and help financial institutions thrive in today’s fast-paced digital landscape,” said Dzung Tran, CEO of FPT Software Europe.
“Vilja is now expanding globally from a strong position as the Nordic market leader and with global recognition for our cloud-native core banking solutions. Our partnership with FPT Software further strengthens this position and is a testimony to our leading innovation and capacity that sends a clear signal to the market. With FPT’s experience, expertise, and trusted reputation we have a global reach starting from Southeast Asia with our focused expansion in the ASEAN countries,” said Fredrik Ulvenholm, CEO of Vilja Solutions.
Boasting over a decade of operation in the European market, FPT Software is now a trusted partner in digital transformation, providing end-to-end services and innovative solutions to more than 150 European leading companies across industries, such as E.ON, Schaeffler, Viessmann, Covestro, Volvo, and Siemens. The IT firm has expanded its presence to nine countries, most recently with the opening of its Swedish office.
The signing ceremony took place at the Vietnam-Sweden Economic Forum in Stockholm, Sweden, with the participation of the Vietnamese Ambassador to Sweden H.E. Tran Van Tuan, Mdm. Camilla Mellander, Director-General for Trade Policy at the Swedish Ministry for Foreign Affairs, FPT Corporation Chairman Dr. Truong Gia Binh, Vilja Chairman Greger Fellin, together with leaders from 50 companies and organizations.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
About Vilja
Vilja technology was created in one of Europe’s first digital banks and is today the leading Nordic cloud-native core banking platform vendor, empowering banks and financial institutions with cutting-edge innovation and digital banking solutions. Our pre-packaged deposit and lending solutions feature a modular design, allowing you to select an end-to-end solution or specific products tailored to your needs. The platform is highly automated and configurable, ensuring rapid time-to-market and enhanced operational efficiency. Our ASEAN headquarters are located in Kuala Lumpur Malaysia. For more information, visit viljasolutions.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909234829/en/
Contacts
Mai Duong (Ms.)
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom